Skip to main content

Gait Disorders, Neurologic

0
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Innovation Pharmaceuticals
1 program
ExerGN/A1 trial
Active Trials
NCT05967078Unknown20Est. Oct 2023
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Femoral Derotation OsteotomyN/A1 trial
Active Trials
NCT03518541Unknown30Est. Dec 2021
Neuron Biopharma
Neuron BiopharmaSpain - Granada
1 program
LexoN/A1 trial
Active Trials
NCT05811494Withdrawn0Est. Aug 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Innovation PharmaceuticalsExerG
Neuron BiopharmaLexo
Heidelberg PharmaFemoral Derotation Osteotomy

Clinical Trials (3)

Total enrollment: 50 patients across 3 trials

ExerG: Video Game-based Physical Cognitive Training for Patients: a Usability Study

Start: May 2023Est. completion: Oct 202320 patients
N/AUnknown

Effectiveness of Multiple Robotic Gait-Devices for Improving Walking Ability in Subacute Stroke Patients

Start: Mar 2023Est. completion: Aug 20240
N/AWithdrawn
NCT03518541Heidelberg PharmaFemoral Derotation Osteotomy

Controlling Femoral Derotation Osteotomy In Cerebral Palsy With Electromagnetic Tracking

Start: Dec 2017Est. completion: Dec 202130 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.